These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4990276)

  • 21. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 22. Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes.
    Lieberman MM
    Antibiot Chemother (1971); 1989; 42():193-202. PubMed ID: 2512837
    [No Abstract]   [Full Text] [Related]  

  • 23. Serological failure of Pseudomonas vaccination in patients receiving multiple chemotherapy.
    Bannister P; Mellor J
    J Biol Stand; 1985 Oct; 13(4):321-6. PubMed ID: 3932361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
    Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
    J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 26. Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.
    Meitert E; Meitert T; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):105-14. PubMed ID: 6816188
    [No Abstract]   [Full Text] [Related]  

  • 27. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine.
    Meitert T; Meitert E; Pencu E; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132
    [No Abstract]   [Full Text] [Related]  

  • 28. [Experimental infection of immunized mice homologous and heterologous serotypes with Pseudomonas aeruginosa].
    Vidal G; Mynard MC
    Ann Inst Pasteur (Paris); 1972 Jun; 122(6):1129-35. PubMed ID: 4627762
    [No Abstract]   [Full Text] [Related]  

  • 29. Experimental investigations on the immunogenicity of some Pseudomonas aeruginosa corpuscular vaccines.
    Meitert E; Meitert T; Petrovici M; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1978; 37(3-4):251-66. PubMed ID: 120167
    [No Abstract]   [Full Text] [Related]  

  • 30. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation.
    Alexander JW; Fisher MW; MacMillan BG
    Arch Surg; 1971 Jan; 102(1):31-5. PubMed ID: 4992359
    [No Abstract]   [Full Text] [Related]  

  • 32. [Specificity of antimicrobial immunity in experimental infection with strains of Pseudomonas aeruginosa].
    Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Sep; (9):89-93. PubMed ID: 65079
    [No Abstract]   [Full Text] [Related]  

  • 33. [Use of a polyvalent vaccine against Pseudomonas aeruginosa in severely burned patients].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1984 Apr; 39(17):557-61. PubMed ID: 6435103
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of polyvalent vaccine against Pseudomonas aeruginosa in extensive burns].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1981 Aug; 36(32):1207-11. PubMed ID: 6798556
    [No Abstract]   [Full Text] [Related]  

  • 35. Vaccinations against Pseudomonas aeruginosa: active and passive alternatives.
    Bellanti JA; Zeligs BJ; Kulczycki LL
    Pediatr Pulmonol Suppl; 1997; 16():269-70. PubMed ID: 9443307
    [No Abstract]   [Full Text] [Related]  

  • 36. The genetic effect of engineered vaccine on Pseudomonas aeruginosa infection in mice.
    Nishio M; Isobe Y; Hatano H; Ohno S; Okuda K; Ishii N
    Immunogenetics; 1993; 38(4):280-2. PubMed ID: 8319977
    [No Abstract]   [Full Text] [Related]  

  • 37. [An experimental study of the immunogenicity of Pseudomonas aeruginosa vaccines].
    Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1976 May; (5):108-13. PubMed ID: 821271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Passive protection of mice against Pseudomonas aeruginosa by serum from recently vaccinated mice.
    Jones RJ; Lilly HA; Lowbury EJ
    Br J Exp Pathol; 1971 Jun; 52(3):264-70. PubMed ID: 4996963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.
    Bauernfeind A; Przyklenk B
    Behring Inst Mitt; 1997 Feb; (98):256-61. PubMed ID: 9382748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.